Anne Schlag - SOMAÍ Pharmaceuticals

An early economic analysis of medical cannabis for the treatment of chronic pain

Authors: S Marrinan, AK Schlag, M Lynskey, C Seaman, MP Barnes, ...

Expert Review of Pharmacoeconomics & Outcomes Research, 1-14

Year: 2024

Allaying the fears: Midomafetamine with therapy is a medicine

Authors: DJ Nutt, T Hawrot, P Hunt, AK Schlag

Drug Science, Policy and Law 10, 20503245241274079

Year: 2024

Psychedelic humanities

Authors: T Noorani, O Davis, A Dymock, N Langlitz, AK Schlag, E Dyck

Frontiers in Psychology 15, 1474064

Year: 2024

Suicidal Ideation in Medicinal Cannabis Patients: A 12-Month Prospective Study

Authors: MT Lynskey, H Thurgur, A Athanasiou-Fragkouli, AK Schlag, DJ Nutt

Archives of Suicide Research, 1-15

Year: 2024

Psychedelic Humanities

Authors: E Dyck, T Noorani, N Langlitz, A Dymock, AK Schlag, O Davis

Frontiers Media SA

Year: 2024

OPEN ACCESS EDITED BY

Authors: AK Schlag, K Greenway, L Fischman, E Jacobs

Psychedelic Humanities, 101

Year: 2024

Prescribed Medical Cannabis Use Among Older Individuals: Patient Characteristics and Improvements in Well-Being: Findings from T21

Authors: MT Lynskey, H Thurgur, A Athanasiou-Fragkouli, AK Schlag, DJ Nutt

Drugs & Aging, 1-10

Year: 2024

Using real world evidence to optimize care: the case of medical cannabis

Authors: AK Schlag, DJ Nutt, M Lynskey

Expert Review of Pharmacoeconomics & Outcomes Research 24 (4), 463-465

Year: 2024

Feasibility of a cannabidiol‐dominant cannabis‐based medicinal product for the treatment of long COVID symptoms: A single‐arm open‐label feasibility trial

Authors: H Thurgur, M Lynskey, AK Schlag, C Croser, DJ Nutt, E Iveson

British Journal of Clinical Pharmacology 90 (4), 1081-1093

Cited by: 2

Year: 2024

Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: real-world evidence

Authors: MT Lynskey, A Athanasiou-Fragkouli, H Thurgur, AK Schlag, DJ Nutt

BJPsych Open 10 (2), e62

Cited by: 1

Year: 2024

Prescribed Medicinal Cannabis for the Treatment of Chronic Pain Comorbid with Depression: Real World Evidence from Project Twenty21

Authors: A Athanasiou-Fragkouli, MT Lynskey, AK Schlag, DJ Nutt

Cited by: 1

Year: 2024

Feasibility of a cannabidiol (CBD)-dominant cannabis-based medicinal product (CBMP) for the treatment of Long COVID symptoms: A single arm open-label feasibility trial.

Authors: H Thurgur, M Lynskey, AK Schlag, C Croser, DJ Nutt, E Iveson

British Journal of Clinical Pharmacology

Year: 2023

Cost-effectiveness of psilocybin-assisted therapy for severe depression: exploratory findings from a decision analytic model

Authors: P McCrone, H Fisher, C Knight, R Harding, AK Schlag, DJ Nutt, JC Neill

Psychological Medicine 53 (16), 7619-7626

Cited by: 12

Year: 2023

Cannabis-based medicinal products (CBMPs) for the treatment of long COVID symptoms: current and potential applications

Authors: H Thurgur, AK Schlag, E Iveson, A Hosseini, M Lynskey, DJ Nutt

Exploration of Medicine 4 (4), 487-503

Cited by: 2

Year: 2023

ARC: a framework for access, reciprocity and conduct in psychedelic therapies

Authors: MJ Spriggs, A Murphy-Beiner, R Murphy, J Bornemann, H Thurgur, ...

Frontiers in Psychology 14, 1119115

Cited by: 10

Year: 2023

Characteristics of and 3-month health outcomes for people seeking treatment with prescribed cannabis: real-world evidence from project Twenty21

Authors: MT Lynskey, AK Schlag, A Athanasiou-Fragkouli, D Badcock, DJ Nutt

Drug Science, Policy and Law 9, 20503245231167373

Cited by: 12

Year: 2023

Risks and adverse events associated with the use of psychedelics

Authors: JC Neill, M Shahid, R Gittins, AK Schlag, FI Tarazi

Psychedelics as Psychiatric Medications, 113

Year: 2023

Medication sparing after medical cannabis initiation: A case study of a chronic pain patient in Project Twenty21

Authors: P Sunderland, DJ Nutt, AK Schlag

Drug Science, Policy and Law 9, 20503245231157489

Cited by: 1

Year: 2023

Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical research

Authors: SL Bourke, AK Schlag, SE O'Sullivan, DJ Nutt, DP Finn

Pharmacology & therapeutics 240, 108216

Cited by: 36

Year: 2022

The value of real world evidence: the case of medical cannabis

Authors: AK Schlag, RR Zafar, MT Lynskey, LD Phillips, DJ Nutt

Frontiers in Psychiatry 13, 1027159

Cited by: 30

Year: 2022

A comparative study of the harms of nitrous oxide and poppers using the MCDA approach

Authors: PM Ferreira, AR Winstock, AK Schlag, B Brandner, G Henderson, I Miller, ...

Drug science, policy and law 8, 20503245221127301

Cited by: 4

Year: 2022

Raising awareness: The implementation of medical cannabis and psychedelics used as an adjunct to standard therapy in the treatment of advanced metastatic breast cancer

Authors: R Zafar, D Sulak, J Brambila, D Nutt, A Schlag

Drug Science, Policy and Law 8, 20503245221114323

Cited by: 2

Year: 2022

A multicriteria decision analysis comparing pharmacotherapy for chronic neuropathic pain, including cannabinoids and cannabis-based medical products

Authors: DJ Nutt, LD Phillips, MP Barnes, B Brander, HV Curran, A Fayaz, DP Finn, ...

Cannabis and cannabinoid research 7 (4), 482-500

Cited by: 43

Year: 2022

Characteristics of people seeking prescribed cannabinoids for the treatment of chronic pain: evidence from project twenty 21

Authors: AK Schlag, M Lynskey, A Fayaz, A Athanasiou-Fragkouli, B Brandner, ...

Frontiers in Pain Research 3, 891498

Cited by: 16

Year: 2022

Developing a real-world evidence base for prescribed cannabis in the United Kingdom: preliminary findings from Project Twenty21

Authors: C Sakal, M Lynskey, AK Schlag, DJ Nutt

Psychopharmacology 239 (5), 1147-1155

Cited by: 44

Year: 2022

Adverse effects of psychedelics: From anecdotes and misinformation to systematic science

Authors: AK Schlag, J Aday, I Salam, JC Neill, DJ Nutt

Journal of Psychopharmacology 36 (3), 258-272

Cited by: 231

Year: 2022

Schedule 1 barriers to research in the UK: An in-depth qualitative analysis

Authors: J Neill, A Howard, A Schlag, C Lennox

Drug Science, Policy and Law 7, 1-13

Year: 2022

Medical cannabis and epilepsy in the UK–A qualitative analysis of the carers’ perspective:“We're asking for quality of life for our children”

Authors: AK Schlag, R Zafar, D Nutt

Drug Science, Policy and Law 7, 20503245211034930

Cited by: 10

Year: 2021

Cannabis based medicines and cannabis dependence: A critical review of issues and evidence

Authors: AK Schlag, C Hindocha, R Zafar, DJ Nutt, HV Curran

Journal of Psychopharmacology 35 (7), 773-785

Cited by: 49

Year: 2021

Current controversies in medical cannabis: Recent developments in human clinical applications and potential therapeutics

Authors: AK Schlag, SE O'Sullivan, RR Zafar, DJ Nutt

Neuropharmacology 191, 108586

Cited by: 64

Year: 2021

A multi criteria decision analysis (MCDA) for evaluating and appraising government policy responses to non medical heroin use

Authors: S Rolles, AK Schlag, F Measham, L Phillips, D Nutt, D Bergsvik, ...

International Journal of Drug Policy 91, 103180

Cited by: 12

Year: 2021

Some contributions on how to formulate drug policies and provide evidence-based regulation

Authors: S Rolles, DJ Nutt, AK Schlag

The American Journal of Bioethics 21 (4), 28-31

Cited by: 2

Year: 2021

Medical cannabis for severe treatment resistant epilepsy in children: a case-series of 10 patients

Authors: R Zafar, A Schlag, L Phillips, DJ Nutt

BMJ Paediatrics Open 5 (1)

Cited by: 11

Year: 2021

Ending the pain of children with severe epilepsy? an audit of the impact of medical cannabis in 10 patients

Authors: RR Zafar, AK Schlag, DJ Nutt

Drug Science, Policy and Law 6, 2050324520974487

Cited by: 14

Year: 2020

Medical cannabis in the UK: from principle to practice

Authors: AK Schlag, DS Baldwin, M Barnes, S Bazire, R Coathup, HV Curran, ...

Journal of Psychopharmacology 34 (9), 931-937

Cited by: 43

Year: 2020

So near yet so far: why won’t the UK prescribe medical cannabis?

Authors: D Nutt, S Bazire, LD Phillips, AK Schlag

BMJ open 10 (9), e038687

Cited by: 53

Year: 2020

Percentages of problem drug use and their implications for policy making: A review of the literature

Authors: AK Schlag

Drug Science, Policy and Law 6, 2050324520904540

Cited by: 61

Year: 2020

An evaluation of regulatory regimes of medical cannabis: what lessons can be learned for the UK?

Authors: AK Schlag

Medical Cannabis and Cannabinoids 3 (1), 76-83

Cited by: 57

Year: 2020

A new approach to formulating and appraising drug policy: a multi-criterion decision analysis applied to alcohol and cannabis regulation

Authors: O Rogeberg, D Bergsvik, LD Phillips, J Van Amsterdam, N Eastwood, ...

International Journal of Drug Policy 56, 144-152

Cited by: 61

Year: 2018

Looking back and going forward: what should the new European Commission do in order to promote evidence-based policy-making?

Authors: R Lofstedt, AK Schlag

Journal of Risk Research 20 (11), 1359-1378

Cited by: 10

Year: 2017

Risk-risk tradeoffs: what should we do in Europe?

Authors: R Lofstedt, A Schlag

Journal of Risk Research 20 (8), 963-983

Cited by: 34

Year: 2017

Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight

Authors: I Singh, C Morgan, V Curran, D Nutt, A Schlag, R McShane

The Lancet Psychiatry 4 (5), 419-426

Cited by: 151

Year: 2017

Europeans and aquaculture: perceived differences between wild and farmed fish

Authors: A Katrin Schlag, K Ystgaard

British Food Journal 115 (2), 209-222

Cited by: 108

Year: 2013

Aquaculture in Europe: media representations as a proxy for public opinion

Authors: AK Schlag

International Journal of Fisheries and Aquaculture 3 (7), 158-165

Cited by: 50

Year: 2011

Aquaculture: an emerging issue for public concern

Authors: AK Schlag

Journal of Risk Research 13 (7), 829-844

Cited by: 98

Year: 2010

Expert and lay representations of GM food: implications for risk communication

Authors: AK Schlag

PQDT-UK & Ireland

Cited by: 4

Year: 2007

“Going back to our roots”. The role of nature in risk perception and risk communication of GM foods

Authors: AK Schlag

Technik in einer fragilen Welt, 495-502

Year: 2005

Authors' response to letter ‘On the use of open‐label studies for the evaluation of cannabis‐based products for the treatment of long‐COVID’

Authors: H Thurgur, M Lynskey, AK Schlag, C Croser, DJ Nutt, E Iveson

British Journal of Clinical Pharmacology

Year: 0

リアルワールドエビデンスの価値: 医療用大麻の場合

Authors: AK Schlag, RR Zafar, MT Lynskey, A Athanasiou-Fragkouli, LD Phillips

Year: 0

Preprint not peer reviewed

Authors: DJ Nutt, AK Schlag, JC Neill, V Chiruta

Year: 0